Innervace
PrivateLast Round
Series A
Sep 8, 2022
Total Funding Raised
$41.1M
Company Overview
Innervace operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Series A round in September 2022.
Innervace is a biotechnology company that develops implantable tissue-engineered brain pathways for the treatment of neurodegenerative disorders.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Innervace Comparables
Compare Innervace with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kenai Therapeutics | 84% | |
| Oryon Cell Therapies | 81% | |
| BE Therapeutics | 81% |
For institutional investors. Book with your work email.
Innervace Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Innervace Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Deerfield Management | Series A |
| IP Group | Series A |
| WARF Ventures | Series A |
| Bio-Reference Laboratories, Inc. | Series A |
| Anzu Partners | Series A |
| Longview Innovation | Series A |
| BioAdvance Capital | Series A |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 8, 2022
$40M round led by Deerfield Management
For institutional investors. Book with your work email.
Innervace Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Innervace's valuation, stock price, and market status.
Is Innervace a public or private company?
Innervace is a private company.
What is the current stock price of Innervace?
Innervace is a private company, so its shares have no public market price. Caplight tracks Innervace's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Innervace worth (valuation)?
Valuation information for Innervace is not publicly available.
Can I buy Innervace stock?
Innervace shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Innervace's last funding round?
Innervace's most recent funding round was Series A on September 8, 2022.
Who are the main investors in Innervace?
Key investors in Innervace include Deerfield Management.
Will Innervace IPO soon?
No public IPO plans have been announced for Innervace.
How can I track Innervace secondary market activity?
Caplight tracks bids, offers, and trades in Innervace's shares on secondary markets.